Anchor Capital Advisors LLC lessened its position in Becton Dickinson and Co (NYSE:BDX) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,928 shares of the medical instruments supplier’s stock after selling 50 shares during the period. Anchor Capital Advisors LLC’s holdings in Becton Dickinson and were worth $488,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in shares of Becton Dickinson and by 0.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock valued at $8,631,529,000 after acquiring an additional 131,536 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Becton Dickinson and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after buying an additional 520,350 shares during the period. Morgan Stanley boosted its holdings in shares of Becton Dickinson and by 66.7% during the 2nd quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after buying an additional 1,955,095 shares during the period. Northern Trust Corp boosted its holdings in shares of Becton Dickinson and by 1.5% during the 2nd quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock worth $824,327,000 after buying an additional 47,202 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Becton Dickinson and by 4.1% during the 2nd quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock worth $731,162,000 after buying an additional 114,398 shares during the period. 84.26% of the stock is owned by institutional investors.
BDX has been the subject of several research analyst reports. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies reduced their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Wells Fargo & Co lifted their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Finally, Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $266.55.
Shares of Becton Dickinson and stock opened at $246.08 on Tuesday. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $264.74. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The company has a 50-day simple moving average of $253.23 and a two-hundred day simple moving average of $246.14. The stock has a market capitalization of $66.38 billion, a price-to-earnings ratio of 22.35, a price-to-earnings-growth ratio of 1.58 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter in the previous year, the company earned $2.91 EPS. The business’s revenue was up 1.7% on a year-over-year basis. On average, sell-side analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.
In other news, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the transaction, the chief executive officer now directly owns 218,671 shares in the company, valued at approximately $56,937,554.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Claire Fraser sold 1,429 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The disclosure for this sale can be found here. Insiders sold a total of 37,249 shares of company stock valued at $9,616,803 in the last quarter. Corporate insiders own 0.12% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Accumulation/Distribution
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.